BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty chemical technology based Life Science Company, announced today that independent lab test results conducted at Microbiotest Inc. of Sterling, Virginia, demonstrated that Ygiene® antimicrobial diluted 1 to 10 with water can totally eradicated the H1N1 Swine Flu virus in 59 seconds on an unclean, soiled surface. The test was performed to determine the effectiveness of Ygiene® specifically against the 2009 H1N1 (swine flu) virus on surfaces that are not pre-cleaned.
Ygiene® is BioNeutral’s broad spectrum antimicrobial currently under development. Ygiene® is undergoing the testing necessary to achieve registration with the Environmental Protection Agency. Ygiene® is thus not yet available on the market.
BioNeutral recognizes the compelling need to provide a cost-effective solution to kill viruses for global applications, especially in developing countries particularly hard hit by the H1N1 swine flu epidemic. Maintaining effectiveness after dilution with water can improve the cost/performance profile while improving the mildness of Ygiene®. BioNeutral’s Ygiene® antimicrobial is one of a few antimicrobials that have reported testing against the specific 2009 H1N1 (swine flu) virus.
Many commercially antimicrobials require an extremely long contact time of 10 minutes to be effective against the flu virus. That contact time is not consistent with normal “wipe down” techniques used by cleaning crews or in households. In contrast, the Ygiene® antimicrobial, being developed by BioNeutral, requires only 59 seconds of contact time, making cleaning and elimination of the virus more realistic in actual use. Whereas many other surface antimicrobials are inactivated by organic material on dirty surfaces, this testing shows BioNeutral’s Ygiene® antimicrobial kills H1N1 quickly even on unclean, contaminated surfaces.
BioNeutral Group CEO, Stephen J. Browand, stated "The validation of this rigorous testing protocol, which utilizes real world “soiled” conditions in a 1 to 10 diluted form, is very exciting. What this will mean is that all countries worldwide will be able to afford an effective combatant to the H1N1 virus, even those with major economic challenges.”
Chief Scientist at BioNeutral Group, Dr. Andrew Kielbania stated “Independent laboratory testing of our Ygiene™ Antimicrobials is an integral aspect of our new product development process and the EPA registration process. These new independent lab results continue to verify the exceptional efficacy and speed to kill of our Ygiene® antimicrobials. Consistent with our strategy on antimicrobial performance we not only actually test against the microorganisms on which we intend to base our EPA application, we also test in the presence of organic soil to better simulate real world conditions. In the end, it is performance in those real world conditions that will distinguish Ygiene® from its competitors.”
New CDC report highlights disparities in flu hospitalization and vaccination